Payment overview · 2025
General Payments
$1,105.23
67 reported records · 9 companies
Healthcare provider profile · identity verified
John P Caster, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SPRINGFIELD, MO · NPI 1902849854
Verified facts
What the public records show
CMS Open Payments records show John P Caster, MD received $1,105.23 in general payments during 2025 across 67 reported records.
Abbott Laboratories accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Mounjaro, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $216.33 | 19.6% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $168.41 | 15.2% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $161.01 | 14.6% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $157.74 | 14.3% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $153.02 | 13.8% | 13 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $141.85 | 12.8% | 8 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $65.39 | 5.9% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.14 | 2.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.34 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,105.23 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $216.33 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $150.68 | 9 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $141.85 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $123.50 | 9 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $112.54 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $76.42 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $75.61 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $68.65 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $45.16 | 3 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $42.30 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $40.48 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $40.48 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.23 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $34.24 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $24.14 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $10.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 40 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 202 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 79 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
40 | 40 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
202 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 591 | 154 |
| Amlodipine Besylate | Amlodipine Besylate | 524 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 495 | 99 |
| Lisinopril | Lisinopril | 487 | 128 |
| Omeprazole | Omeprazole | 365 | 92 |
| Gabapentin | Gabapentin | 336 | 78 |
| Losartan Potassium | Losartan Potassium | 267 | 70 |
| Trazodone Hcl | Trazodone Hcl | 245 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 233 | 64 |
| Simvastatin | Simvastatin | 227 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 210 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 210 | 57 |
| Eliquis | Apixaban | 202 | 36 |
| Sertraline Hcl | Sertraline Hcl | 188 | 43 |
| Metformin Hcl Er | Metformin Hcl | 179 | 45 |
| Carvedilol | Carvedilol | 175 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 168 | 41 |
| Potassium Chloride | Potassium Chloride | 166 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 164 | 38 |
| Metformin Hcl | Metformin Hcl | 159 | 43 |
| Allopurinol | Allopurinol | 140 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 35 |
| Alendronate Sodium | Alendronate Sodium | 131 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 123 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 49 |
| Spironolactone | Spironolactone | 101 | 18 |
| Tramadol Hcl | Tramadol Hcl | 101 | 28 |
| Furosemide | Furosemide | 100 | 26 |
| Meloxicam | Meloxicam | 91 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 86 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 23 |
| Atenolol | Atenolol | 84 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 20 |
| Buspirone Hcl | Buspirone Hcl | 81 | 18 |
| Ozempic | Semaglutide | 79 | 13 |
| Jardiance | Empagliflozin | 78 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 74 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 73 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 65 | 13 |
| Famotidine | Famotidine | 63 | 14 |
| Montelukast Sodium | Montelukast Sodium | 62 | 16 |
| Donepezil Hcl | Donepezil Hcl | 55 | suppressed |
| Lovastatin | Lovastatin | 54 | 15 |
| Glimepiride | Glimepiride | 52 | suppressed |
| Pregabalin | Pregabalin | 52 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 51 | 12 |
| Rybelsus | Semaglutide | 51 | suppressed |
| Valsartan | Valsartan | 51 | 13 |
| Azithromycin | Azithromycin | 49 | 40 |
| Trulicity | Dulaglutide | 45 | suppressed |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Synthroid | Levothyroxine Sodium | 42 | 11 |
| Ondansetron Odt | Ondansetron | 41 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 40 | 40 |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Chlorthalidone | Chlorthalidone | 37 | suppressed |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 16 |
| Tradjenta | Linagliptin | 34 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 33 | suppressed |
| Irbesartan | Irbesartan | 33 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Cephalexin | Cephalexin | 31 | 28 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | 13 |
| Methylprednisolone | Methylprednisolone | 30 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 26 |
| Finasteride | Finasteride | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 25 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 24 | 24 |
| Alprazolam | Alprazolam | 24 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 24 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,105.23 · 67 records | Abbott Laboratories | AIRSUPRA, AREXVY, BREZTRI, Dexcom G6 Transmitter, ELIQUIS, FABRAZYME, FARXIGA, FREESTYLE LIBRE, INSPIRE, KISUNLA, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, Wegovy, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error